These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29264984)

  • 1. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate.
    Teltayev D; Akshulakov S; Ryskeldiev N; Mustafin K; Vyacheslav L
    Gynecol Endocrinol; 2017; 33(sup1):50-51. PubMed ID: 29264984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma.
    Li ZQ; Quan Z; Tian HL; Cheng M
    J Int Med Res; 2012; 40(2):517-24. PubMed ID: 22613412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of acromegaly in pregnant woman].
    Ben Salem Hachmi L; Kammoun I; Bouzid C; Smida H; Nagi S; Turki Z; Ben Slama C
    Ann Endocrinol (Paris); 2010 Feb; 71(1):60-3. PubMed ID: 19926070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial.
    Mao ZG; Zhu YH; Tang HL; Wang DY; Zhou J; He DS; Lan H; Luo BN; Wang HJ
    Eur J Endocrinol; 2010 Apr; 162(4):661-6. PubMed ID: 20061334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
    Lucas T; Astorga R; Catalá M;
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma].
    Zieliński G; Podgórski JK; Koziarski A; Siwik J; Zgliczyński W; Wieliczko W
    Neurol Neurochir Pol; 2001; 35(3):423-37. PubMed ID: 11732266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
    Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
    Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
    An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
    BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
    J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].
    Wasko R; Sawicka J; Stachowiak C; Kozak W; Junik R; Sowinski J
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):532-5. PubMed ID: 12527855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.